



## New funds from Nyrada share sale

### Highlights

- Strategic decision raises almost \$2.5 million
- HERACLES clinical trial starting soon
- Funds for R&D pipeline

**Sydney, 20 May 2025:** Innovative biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce it has raised additional working capital by disposing of its entire shareholding in Nyrada Inc (ASX:NYR).

This strategic decision has generated nearly \$2.5 million in non-dilutive funds, enabling the company to continue pursuing its objectives such as starting the upcoming [HERACLES clinical trial](#) and investing in its R&D pipeline.

Noxopharm CEO Dr Gisela Mautner said: “Over the past 18 months we have gained significant momentum, and the sale of these shares will support our operations as we continue to invest in our innovative technology.

“We would like to thank Canary Capital for their assistance in completing this transaction and are grateful for their support throughout this process.”

**-ENDS-**

### About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

#### Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: [julian.elliott@noxopharm.com](mailto:julian.elliott@noxopharm.com)

#### Company Secretary:

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

*Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.